Navigation Links
Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Date:7/19/2011

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to patients in any global market.

Edoxaban is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Results from clinical studies supported the approval of edoxaban for the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.

"Today's launch of edoxaban marks the global debut of the medication, which is an exciting breakthrough for patients who require VTE prevention after major orthopedic surgery," said Joji Nakayama, president and CEO of Daiichi Sankyo. "Edoxaban demonstrates solid efficacy in clinical trials (2, 3) in this population of patients. Its predictable pharmacokinetic and pharmacodynamic profile allows for a convenient, once-daily dosing."

The global clinical development program for edoxaban is focused on several indications, including stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent VTE. Edoxaban is currently being assessed in the Phase III ENGAGE AF-TIMI 48 study (4), an ongoing, multinational, randomized, double-blind trial evaluating the efficacy and safety of edoxaban in preventing stroke and systemic embolic events in patients with AF. More than 21,000 patients with AF in 46 countries are being examined, making this the largest trial in this indication to date. In addition, Daiichi Sankyo is currently enrolling patients in its HOKUSAI VTE study (5)
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...
Medicine Products: